Canada markets close in 44 minutes

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
85.45+1.45 (+1.73%)
As of 01:23PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close84.00
Open84.62
Bid0.00 x 0
Ask0.00 x 0
Day's Range84.62 - 85.45
52 Week Range78.78 - 95.00
Volume978
Avg. Volume26,562
Market Cap193.695B
Beta (5Y Monthly)0.56
PE Ratio (TTM)19.74
EPS (TTM)4.33
Earnings DateN/A
Forward Dividend & Yield3.22 (3.84%)
Ex-Dividend DateMar. 04, 2021
1y Target EstN/A
  • Motley Fool

    2 Cheap Dividend Stocks With Yields Above 3%

    For example, at their current share prices, both Novartis (NYSE: NVS) and Chevron (NYSE: CVX) yield more than 3%. If you buy shares of Novartis today, you'll collect around 3.7% just in dividend income at the current payout level. The pharmaceutical company has increased its annual dividend payments for 24 years in a row -- and a hike this year would make it a Dividend Aristocrat.

  • GlobeNewswire

    Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil

  • Zacks

    Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA

    The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.